このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC (PATAGONIA)

2026年11月10日 更新者:AstraZeneca

A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-Based Combinations in Adult Participants With TROP2 NMR-positive Non-small Cell Lung Cancer (NSCLC) (PATAGONIA)

Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

This is a Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.

This study is designed as non-comparative.

Participants will be randomised to Treatment A or B.

In the module 1 of this study, Dato-DXd-based regimens will be assessed in participants with non-AGA NSCLC whose tumours have been prospectively identified as TROP2 NMR+.

The proposed primary objectives are to assess the efficacy of Dato-DXd combined with durvalumab and carboplatin and Dato-DXd combined with durvalumab in terms of PFS per RECIST 1.1 as assessed by the investigator.

Participants in both treatment groups will receive study treatment medicines until investigator-assessed radiological progression per RECIST 1.1, unacceptable toxicity, withdrawal of consent, or an intervention discontinuation criterion is met. There is no maximum limit to the number of cycles of Dato-DXd and/or durvalumab that a participant in either treatment group can receive. The maximum treatment for carboplatin is 4 cycles.

The study will be conducted in several countries worldwide.

研究の種類

介入

入学 (推定)

250

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • Irvine、California、アメリカ、92618
        • Research Site
      • Oakland、California、アメリカ、94612
        • Research Site
    • Colorado
      • Golden、Colorado、アメリカ、80401
        • Research Site
    • Connecticut
      • New Haven、Connecticut、アメリカ、06519
        • Research Site
    • Florida
      • Miami、Florida、アメリカ、33170
        • Research Site
      • Tampa、Florida、アメリカ、33612
        • Research Site
    • Georgia
      • Atlanta、Georgia、アメリカ、30318
        • Research Site
    • Illinois
      • Peoria、Illinois、アメリカ、61637
        • Research Site
    • South Carolina
      • Greer、South Carolina、アメリカ、29651
        • Research Site
      • Greer、South Carolina、アメリカ、29650
        • Research Site
    • Texas
      • Sugar Land、Texas、アメリカ、77479
        • Research Site
    • Utah
      • Salt Lake City、Utah、アメリカ、84112
        • Research Site
    • West Virginia
      • Morgantown、West Virginia、アメリカ、26506
        • Research Site
      • Ciudad Autonoma Buenos Aires、アルゼンチン、1405
        • Research Site
      • Ciudad de Buenos Aires、アルゼンチン、C1427ARO
        • Research Site
      • La Rioja、アルゼンチン、5300
        • Research Site
      • Rosario、アルゼンチン、2000
        • Research Site
      • Rosario、アルゼンチン、S2000KZE
        • Research Site
      • San Juan、アルゼンチン、5400
        • Research Site
      • Viedma、アルゼンチン、R8500ACE
        • Research Site
      • Lucca、イタリア、55100
        • Research Site
      • Orbassano、イタリア、10043
        • Research Site
      • Parma、イタリア
        • Research Site
      • Rozzano、イタリア、20089
        • Research Site
      • Torrette、イタリア、60126
        • Research Site
      • Verona、イタリア、37126
        • Research Site
      • Adelaide、オーストラリア、5000
        • Research Site
      • Bedford Park、オーストラリア、5042
        • Research Site
      • Southport、オーストラリア、4215
        • Research Site
      • Waratah、オーストラリア、2298
        • Research Site
      • Woodville、オーストラリア、5011
        • Research Site
    • Alberta
      • Edmonton、Alberta、カナダ、T6G 1Z2
        • Research Site
    • Ontario
      • Brampton、Ontario、カナダ、L6R 3J7
        • Research Site
      • Toronto、Ontario、カナダ、M4N 3M5
        • Research Site
    • Quebec
      • Montreal、Quebec、カナダ、H3T 1M5
        • Research Site
      • Singapore、シンガポール、119228
        • Research Site
      • Singapore、シンガポール、308433
        • Research Site
      • Singapore、シンガポール、217562
        • Research Site
      • Singapore、シンガポール、168583
        • Research Site
      • Marseille、フランス、13273
        • Research Site
      • Nice、フランス、06000
        • Research Site
      • Paris、フランス、75014
        • Research Site
      • Paris、フランス、75005
        • Research Site
      • Pessac、フランス、33604
        • Research Site
      • Villefranche-sur-Saône、フランス、69655
        • Research Site
      • Blumenau、ブラジル、89010-340
        • Research Site
      • Curitiba、ブラジル、80810-050
        • Research Site
      • Ijuí、ブラジル、98700-000
        • Research Site
      • Porto Alegre、ブラジル、90610-000
        • Research Site
      • Porto Alegre、ブラジル、91350200
        • Research Site
      • Rio de Janeiro、ブラジル、22281-100
        • Research Site
      • Salvador、ブラジル、40170-110
        • Research Site
      • Santa Maria、ブラジル、97015-450
        • Research Site
      • São Paulo、ブラジル、01246-000
        • Research Site
      • São Paulo、ブラジル、01509-900
        • Research Site
      • São Paulo、ブラジル、03102-006
        • Research Site
      • Teresina、ブラジル、64049-200
        • Research Site
      • Vitória、ブラジル、29043-260
        • Research Site
      • Lodz、ポーランド、93-338
        • Research Site
      • Lodz、ポーランド、93-513
        • Research Site
      • Przemyśl、ポーランド、37-700
        • Research Site
      • Warsaw、ポーランド、00-124
        • Research Site
      • Beijing、中国、100730
        • Research Site
      • Beijing、中国、100191
        • Research Site
      • Changchun、中国、130021
        • Research Site
      • Changsha、中国、410013
        • Research Site
      • Chengdu、中国、610041
        • Research Site
      • Chongqing、中国、400030
        • Research Site
      • Guangzhou、中国、510000
        • Research Site
      • Hangzhou、中国、310009
        • Research Site
      • Harbin、中国、150081
        • Research Site
      • Nanchang、中国、330000
        • Research Site
      • Nanning、中国、530021
        • Research Site
      • Shandong、中国
        • Research Site
      • Shanghai、中国、200032
        • Research Site
      • Shanghai、中国、200030
        • Research Site
      • Tianjin、中国、300051
        • Research Site
      • Wuhan、中国、430022
        • Research Site
      • Yangzhou、中国、225001
        • Research Site
      • Zhengzhou、中国、450008
        • Research Site
      • Zhengzhou、中国、450000
        • Research Site
      • Cheongju-si、韓国、28644
        • Research Site
      • Jinju、韓国、660-702
        • Research Site
      • Seongnam-si、韓国、13620
        • Research Site
      • Seoul、韓国、5505
        • Research Site
      • Seoul、韓国、120-749
        • Research Site
      • Suwon、韓国、16247
        • Research Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

INCLUSION CRITERIA:

  1. Participant must be ≥ 18 years of age at the time of signing the ICF.

  2. Pathologically documented NSCLC that:

    1. Has documented non-squamous histology
    2. Is TROP2 NMR positive
    3. Documented lack of sensitising EGFR mutation, as well as ALK and ROS1 rearrangements on tumour tissue.
  3. Stage IIIB or IIIC disease not amenable to surgical resection or definitive chemoradiation, or Stage IV metastatic NSCLC at the time of randomisation, as per the American Joint Committee on Cancer Staging System, 9th Edition.

  4. The ECOG PS of 0 to 2.

  5. Known tumour PD-L1 status.

  6. Minimum life expectancy of 12 weeks.

  7. Provision of acceptable FFPE tumour sample from a lesion not previously irradiated.

  8. At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline.

  9. Adequate bone marrow reserve and organ function.

  10. Contraceptive use by participants or participant partners.

  11. Capable of giving signed informed consent.

  12. Provision of signed and dated optional informed consent.

EXCLUSION CRITERIA:

  1. As judged by the investigator, any evidence of diseases, chronic diverticulitis or previous complicated diverticulitis, or history of allogenic organ transplant, which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.

  2. History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, lentigo maligna that has undergone potentially curative therapy, or adequately treated in situ disease without evidence of disease.

  3. Squamous histology or mixed SCLC and NSCLC, or sarcomatoid variant of NSCLC, or lung neuroendocrine tumours .

  4. Has documented tumour genomic alterations in EGFR, ALK, ROS1, NTRK, BRAF V600E, RET, MET exon 14, or any other actionable driver oncogenes for which there are locally approved and available targeted first-line therapies.

    Note: Participants whose tumours harbour KRAS mutations are eligible for the study

  5. Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia or vitiligo, not yet improved to Grade ≤ 1 or baseline.

  6. Active or prior documented autoimmune, connective tissue or inflammatory disorders, autoimmune pneumonitis, or autoimmune myocarditis.

  7. Spinal cord compression or CNS metastases, unless asymptomatic, stable, and not requiring treatment with corticosteroids or anticonvulsants for at least 7 days prior to randomisation.

  8. History of leptomeningeal carcinomatosis or metastasis.

  9. Clinically significant corneal disease.

  10. Has active or uncontrolled HBV or HCV infection.

  11. Known HIV infection that is not well controlled.

  12. Uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals, suspected infections or inability to rule out infections.

  13. Known to have active tuberculosis infection.

  14. Mean resting QTcF > 470 ms, regardless of gender, obtained from triplicate 12-lead ECGs performed at screening.

  15. Uncontrolled or significant cardiac disease.

  16. History of ILD/pneumonitis.

  17. Has clinically severe pulmonary function compromised.

  18. Prior exposure to:

    1. Any agent, including ADC, containing a chemotherapeutic agent targeting topoisomerase I
    2. Chemotherapy or any other systemic therapy for first-line Stage IIIB, IIIC, or IV NSCLC
    3. TROP2-targeted therapy
    4. Chloroquine/hydroxychloroquine without an adequate treatment washout period.
  19. Participants who have received any prior adjuvant, neoadjuvant, or definitive chemoradiation for early stage disease (Stage I to III) are eligible, provided they meet the protocol-defined conditions.

  20. Current or prior use of immunosuppressive medication within 14 days before the first dose of study intervention.

  21. Any concurrent anti-cancer treatment.

  22. Any concomitant medication known to be associated with Torsades de Pointes.

  23. Receipt of live, attenuated vaccine within 30 days prior to the first dose of study intervention.

  24. Received prior radiotherapy to the brain within 2 weeks of start of study intervention or received palliative radiotherapy to the chest within 4 weeks of start of study intervention or has ongoing radiation-related toxicities requiring corticosteroids.

  25. Major surgical procedure or significant traumatic injury within ≤ 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.

  26. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to randomisation or concurrent participation in another clinical study.

  27. Participants with a known history of severe hypersensitivity reactions to study intervention or any excipients of these products.

  28. Participants with a known history of severe hypersensitivity reactions to other monoclonal antibodies.

  29. Allocation to a stratum that has reached the cap.

  30. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

  31. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

  32. For females only: Is pregnant (confirmed with positive serum pregnancy test), or breastfeeding, or planning to become pregnant.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment A

Participants will receive Dato-DXd and durvalumab Q3W on Day 1 of every 21-day cycle.

Treatment A/B: Dato-DXd as IV infusion.

他の名前:
  • ダトポタマブ デルクステカン

Treatment A/B: Durvalumab as IV infusion

実験的:Treatment B

Participants will receive Dato-DXd, durvalumab, and carboplatin Q3W on Day 1 of every 21-day cycle for the first 4 cycles, followed by Dato-Dxd and durvalumab Q3W

Treatment A/B: Dato-DXd as IV infusion.

他の名前:
  • ダトポタマブ デルクステカン

Treatment A/B: Durvalumab as IV infusion

Treatment B: Carboplatin as IV infusion

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
PFS as assessed by investigator on Treatment A
時間枠:Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

PFS is defined as time from date of first dose of any study treatment until progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause.

Primary measure of interest is the median PFS.

Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
PFS as assessed by investigator on Treatment B
時間枠:Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

PFS is defined as time from date of first dose of any study treatment until progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause.

Primary measure of interest is the median PFS.

Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Objective Response rate (ORR) in each treatment arm
時間枠:Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

ORR is defined as the proportion of participants who have a confirmed response (CR or PR), as determined by the investigator at local site per RECIST 1.1.

For each study treatment group, the primary measure of interest is the estimate of ORR.

Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
Duration of response (DoR) in each treatment arm
時間枠:Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

DoR is defined as the time from the date of first documented confirmed response until the date of documented progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause.

For each study treatment group, the primary measure of interest is the median DoR.

Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

その他の成果指標

結果測定
メジャーの説明
時間枠
Safety as measured by the number of patients with at least one adverse event (AE), by study treatment
時間枠:Date of first dose of study intervention until earliest of 90 days after study treatment discontinuation, death or end of study, up to approximately 30 months

Proportion of patients with at least one AE

Date of first dose of study intervention until earliest of 90 days after study treatment discontinuation, death or end of study, up to approximately 30 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月30日

一次修了 (推定)

2028年12月16日

研究の完了 (推定)

2028年12月22日

試験登録日

最初に提出

2026年9月3日

QC基準を満たした最初の提出物

2026年11月10日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • D9260C00007
  • 2025 (米国 NIH グラント/契約)
  • 2025-524836-21 (レジストリ識別子:CTIS (EU))

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

IPD 共有時間枠

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共有アクセス基準

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。